The anti-idiotype vaccines for immunotherapy.
Certain anti-idiotypic antibodies that bind to the antigen-combining sites of antibodies can effectively mimic the three-dimensional structures and functions of the external antigens and can be used as surrogate antigens for active specific immunotherapy. Extensive studies in animal models have demonstrated the efficacy of these vaccines for triggering the immune system to induce specific and protective immunity against bacterial, viral and parasitic infections as well as tumors. Several monoclonal anti-idiotype antibodies that mimic distinct human tumor-associated antigens have been developed and characterized. Encouraging results have been obtained in recent clinical trials using these anti-idiotype antibodies as vaccines. In this article, we will review the current literature and discuss the potential of this novel therapeutic approach for various human cancers.
Bhattacharya-Chatterjee
M
M
Department of Internal Medicine and the Barrett Cancer Center, University of Cincinnati, Cincinnati, OH 45267-0509, USA. malaya.chatterjee@uc.edu
Chatterjee
S K
SK
Foon
K A
KA
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000628:therapy; D019496:Cancer Vaccines / Q000627:therapeutic use; D018288:Carcinoma, Small Cell / Q000628:therapy; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000628:therapy; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008175:Lung Neoplasms / Q000628:therapy; D008545:Melanoma / Q000628:therapy; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D019496:Cancer Vaccines